This study aims to evaluate how Risankizumab, a medication used to treat Crohn's Disease, works in children. It focuses on understanding how factors such as age, weight, and the way the drug is processed in the body may influence its effectiveness and safety in pediatric patients.

This study aims to prospectively explore the real life short and longer term outcomes of Vedolizumab in pediatric inflammatory bowel disease and to develop a prediction model for treatment success based on Vedolizumab trough levels and other clinical and laboratory markers. Children under 18 years of age that have been diagnosed with IBD and their physician is starting treatment with Vedolizumab may be eligible.